| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S1461145713000837 |
| P698 | PubMed publication ID | 24044761 |
| P50 | author | Hans-Jürgen Möller | Q1577771 |
| Florian Seemüller | Q41595364 | ||
| P2093 | author name string | E Rüther | |
| R Grohmann | |||
| R Schennach-Wolff | |||
| S Stübner | |||
| P2860 | cites work | Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review | Q24598636 |
| Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression | Q28254016 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness | Q28274600 | ||
| Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs | Q28305100 | ||
| Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response | Q28306033 | ||
| The AMUP study for drug surveillance in psychiatry - a summary of inpatient data | Q30917406 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia | Q33223628 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia | Q33235110 | ||
| Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. | Q33288908 | ||
| Cost of antipsychotic polypharmacy in the treatment of schizophrenia | Q33327172 | ||
| Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. | Q33385675 | ||
| Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression | Q33386563 | ||
| Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients | Q33506751 | ||
| Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data | Q33676260 | ||
| The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study | Q33850634 | ||
| Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. | Q34088016 | ||
| National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 | ||
| A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation | Q34298891 | ||
| Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs | Q34338202 | ||
| Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. | Q34447495 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment | Q34550618 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care | Q34578945 | ||
| Therapeutic options for treatment-resistant depression | Q34615947 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression | Q34616633 | ||
| World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia | Q34744755 | ||
| Systematic of psychiatric disorders between categorical and dimensional approaches: Kraepelin's dichotomy and beyond | Q34783420 | ||
| Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations | Q34941330 | ||
| Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials | Q34997918 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression | Q35024109 | ||
| Predictive factors for polypharmacy among child and adolescent psychiatry inpatients | Q35060149 | ||
| Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior | Q35175610 | ||
| Management of the negative symptoms of schizophrenia: new treatment options | Q35201017 | ||
| Half a century of antipsychotics and still a central role for dopamine D2 receptors | Q35595235 | ||
| The AMSP drug safety program: methods and global results | Q35723762 | ||
| Atypical antipsychotic dosing: the effect of smoking and caffeine | Q35765265 | ||
| Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? | Q36183110 | ||
| Treatment of depression with atypical features: a meta-analytic approach | Q36328170 | ||
| Innovative approaches for the development of antidepressant drugs: current and future strategies | Q36401400 | ||
| Polypharmacy trends in office visits by the elderly in the United States, 1990 and 2000. | Q36670163 | ||
| Emerging treatments for major depression | Q36730674 | ||
| A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness | Q36783867 | ||
| Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research | Q36840610 | ||
| Evidence of agomelatine's antidepressant efficacy: the key points | Q36961526 | ||
| Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature | Q37038719 | ||
| Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim | Q37075859 | ||
| When is antipsychotic polypharmacy supported by research evidence? Implications for QI. | Q37306729 | ||
| Polypharmacy with second-generation antipsychotics: a review of evidence | Q37341522 | ||
| Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic | Q37356659 | ||
| Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia | Q37358657 | ||
| Second-generation antipsychotics for schizophrenia: can we resolve the conflict? | Q37428125 | ||
| Is evidence sufficient for evidence-based medicine? | Q37624453 | ||
| Antipsychotic polypharmacy in schizophrenia: benefits and risks | Q37863093 | ||
| Pharmacotherapy of schizophrenic patients: achievements, unsolved needs, future research necessities | Q37979290 | ||
| Does early improvement in major depression protect against treatment emergent suicidal ideation? | Q39296317 | ||
| Chemical brain anatomy in schizophrenia | Q40473365 | ||
| Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? | Q41685984 | ||
| Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder | Q43166292 | ||
| Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort | Q43930301 | ||
| Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction | Q44097688 | ||
| Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations | Q44451644 | ||
| Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial | Q45155086 | ||
| Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. | Q46087064 | ||
| Aripiprazole in combination with other antipsychotic drugs may worsen psychosis | Q46105549 | ||
| How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs | Q46380111 | ||
| Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology? | Q46508028 | ||
| Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidon | Q46553469 | ||
| Dual-isotope SPECT imaging of striatal dopamine: first episode, drug naïve schizophrenic patients. | Q46847750 | ||
| Clozapine alone versus clozapine and risperidone with refractory schizophrenia | Q46923458 | ||
| Outcomes of 1014 naturalistically treated inpatients with major depressive episode | Q48374102 | ||
| The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy | Q48700932 | ||
| Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy | Q50112124 | ||
| The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial. | Q50889035 | ||
| A pilot study testing a medication algorithm to reduce polypharmacy. | Q51852498 | ||
| Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog | Q51864697 | ||
| Is there a need for a new psychiatric classification at the current state of knowledge? | Q51887488 | ||
| Validation of polypharmacy process measures in inpatient schizophrenia care. | Q51929063 | ||
| Reasons for polypharmacy among psychiatric patients. | Q51939558 | ||
| Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992 2002 | Q55953463 | ||
| Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries | Q57470966 | ||
| Emerging drugs for schizophrenia | Q59739113 | ||
| Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study | Q60621934 | ||
| Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. | Q64941517 | ||
| Antipsychotic polypharmacy, part 2: tips on use and misuse | Q73022999 | ||
| Elevated plasma levels of clozapine after concomitant use of fluvoxamine | Q73154892 | ||
| Advances in the pharmacogenetic prediction of antipsychotic response | Q79086013 | ||
| Polypharmacy: when is it rational? | Q80112030 | ||
| Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital | Q82206423 | ||
| Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study | Q83294329 | ||
| Is monotherapy as good as polypharmacy in long-term treatment of bipolar disorder? | Q84980476 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 983-996 | |
| P577 | publication date | 2013-09-18 | |
| P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
| P1476 | title | History, background, concepts and current use of comedication and polypharmacy in psychiatry | |
| P478 | volume | 17 |
| Q50535588 | A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. |
| Q50089992 | Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography |
| Q55037377 | Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. |
| Q50232186 | EPA guidance on improving the image of psychiatry |
| Q50644981 | Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium. |
| Q90030941 | Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders |
Search more.